Fig. 5: Comparison of the effectiveness of OV-αCD47-G1 versus OV-αCD47-G4 to improve in vivo oncolytic virotherapy of GBM in an orthotopic model of human GBM.
a Experimental timeline for in vivo studies. An orthotopic model of human GBM was established by i.c. injection of 1 × 105 GBM43-FFL human GBM cells into athymic nude mice. Seven days later, mice were intratumorally injected with vehicle control or 2 × 105 PFU of OV-Q1, OV-αCD47-G1, or OV-αCD47-G4. b Time-lapse luciferase imaging of GBM43-FFL growth in mice with indicated treatments. c Survival of GBM43-FFL tumor-bearing mice treated as described in (a). Survival was estimated by the Kaplan–Meier method and compared by two-side log-rank test (n = 9 animals). *Two mice in the OV-Q1 control group died accidentally after i.p. injection of luciferin on days 16 and 27 without obvious GBM symptoms. d Individual body weights of the experimental mice were recorded once every other day.
